Revolution Medicines' Daraxonrasib Cuts Pancreatic Cancer Death Risk by 60% – This Week in Biotech #96
The most compelling pancreatic cancer trial result in a decade, Lilly's oral GLP-1 eyes a diabetes label, and the FDA is reconsidering compounding restrictions (April 10-16, 2026).
Welcome back to This Week in Biotech by Biotech Blueprint, edition 96, covering biotech and biopharma news from April 10th to 16th, 2026.
🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.
🌐 For consulting inquiries, please email us or visit BiotechBlueprintConsulting.com.
👥 If you haven’t already, please connect with me or follow me on LinkedIn.
VIDEO SUMMARY
THIS WEEK’S KEY TAKEAWAYS 🔑
April 13 may turn out to be one of the more important single days in pancreatic cancer research in a generation. Revolution Medicines posted a landmark Phase 3 result in second-line metastatic pancreatic cancer, a disease where chemotherapy produces median overall survival of roughly six to seven months, and where nothing has meaningfully moved that number in over a decade. The trial posted 13.2 months, with a hazard ratio of 0.40, meaning a 60% reduction in the risk of death versus chemotherapy, delivered as a once daily oral pill. If this holds through full data review, daraxonrasib becomes the standard of care for RAS-mutant second-line pancreatic cancer, which is essentially all of it, and Revolution becomes a serious acquisition target.
On the same morning, IDEAYA Biosciences reported a clean Phase 3 readout in uveal melanoma, a rare eye cancer with no approved first-line treatment for the relevant patient subgroup. The overall response rate was 37.1% versus 5.8% for investigator’s choice, with a hazard ratio of 0.42 on progression-free survival. Smaller population than pancreatic cancer, but an equally unambiguous result. An NDA filing is targeted for the second half of 2026. Two clean results in two notoriously hard indications on the same morning is not something that happens often.
The Foundayo story moved forward on two fronts. The FDA asked Lilly for post-marketing studies covering liver injury, thyroid cancer risk, and long-term cardiovascular outcomes, which is standard for a new mechanism being deployed at massive scale, not a red flag. Lilly responded with ACHIEVE-4, their largest and longest orforglipron trial to date: 2,749 patients with type 2 diabetes and elevated cardiovascular risk, non-inferior cardiovascular outcomes versus insulin glargine, no liver signal, 8.1 kg of weight loss versus a 1.4 kg gain on the comparator, and all-cause mortality 57% lower with Foundayo, though that last number wasn’t controlled for multiple comparisons and should be read carefully. The T2D filing is on track for Q2.
On the policy side, the FDA scheduled an advisory committee review to reconsider restrictions on several compounded peptides that were flagged for safety concerns back in 2023. The practical read is that compounding boundaries directly affect demand for branded alternatives, safety narratives around entire drug classes, and how aggressively telehealth platforms can operate. When those boundaries get revisited, it creates real uncertainty for companies that have been planning around the existing framework. On the capital side, the market is open but selective. Revolution pulled in a $2B financing on the back of its Phase 3 data in a single move, while smaller players like MeiraGTx had to get creative with asset reacquisitions and targeted equity raises. Lilly also added to its oncology portfolio, acquiring CrossBridge Bio for up to $300M to get its hands on a dual-payload TROP2 antibody drug conjugate at the pre-IND stage. Small deal, but consistent with a deliberate pattern of building out targeted delivery capabilities before the competitive window closes.
BIOTECH/PHARMA NEWS 🧬
🔹 In an unusual reversal of the typical deal direction, MeiraGTx announced on April 16 that it is acquiring botaretigene sparoparvovec (bota-vec) back from J&J for $25M upfront, with a single milestone payment due on U.S. approval and royalties to J&J starting in mid-2029. Bota-vec is an AAV-based gene therapy targeting RPGR-associated X-linked retinitis pigmentosa (XLRP), a rare inherited retinal disease causing progressive vision loss in an estimated 20k patients in the U.S. and EU with no approved treatment. The FDA has granted Fast Track and Orphan Drug Designations; the EU has granted PRIME and ATMP designations. MeiraGTx targets regulatory filings in the U.S. and EU in 2027. For MeiraGTx, this clears the path to commercialize a program it originated.
🔹 The FDA scheduled advisory committee review to reconsider restrictions on several compounded peptides that had been placed in a category associated with significant safety concerns in 2023. The agency is moving to reclassify multiple substances, with meetings planned in 2026 and early 2027. This is a policy volatility signal for biopharma and telehealth alike, because compounding boundaries influence demand flows, safety narratives, and future enforcement assumptions.
🔹 Lilly announced on April 14 the acquisition of CrossBridge Bio, a Houston-based startup spun out of UTHealth Houston, for up to $300M in cash (upfront plus a development milestone). CrossBridge’s lead asset is CBB-120, a TROP2-targeting antibody-drug conjugate (ADC) that delivers two payloads simultaneously: a topoisomerase 1 inhibitor and an ATR kinase inhibitor. The crowded TROP2 ADC space already has two approved single-payload drugs in Trodelvy and Datroway, and the bet with CBB-120 is that hitting two biological targets simultaneously generates more durable responses and makes it harder for tumors to develop resistance. IND filing for CBB-120 is targeted for 2026. This is Lilly’s latest oncology platform add, following its ongoing expansion into degraders and conjugate hybrids. Section 232 tariff exemptions for ADCs further advantage this category. The deal is expected to close in Q2 2026.
🔹 Roche said it will launch a new global Phase 3 trial for Elevidys in early ambulatory Duchenne muscular dystrophy patients, randomizing about 100 participants to Elevidys or placebo over 72 weeks with time-to-rise as the primary endpoint. The study is designed to support a resubmission in Europe after the prior negative opinion from the EMA. This resets expectations for a longer and more data-intensive European path and reinforces that gene therapy commercialization is now a multi-cycle evidence process.
🔹 Replimune began layoffs after receiving a second complete response letter on RP1 in advanced melanoma, including a reported reduction of 63 employees this month, while management continues to argue the therapy’s activity profile remains clinically meaningful. This is the execution penalty in real time when accelerated approval strategy fails to align with regulator expectations.
CLINICAL TRIAL UPDATES 📊
🔹 Daraxonrasib (Revolution Medicines) - Phase 3 [RASolute 302], 2L metastatic pancreatic ductal adenocarcinoma (PDAC). In what may be the most important oncology data package of 2026 so far, Revolution Medicines announced on April 13 that its RAS(ON) multi-selective inhibitor daraxonrasib met both primary endpoints in the RASolute 302 Phase 3 trial: statistically significant improvement in both progression-free survival and overall survival (OS) versus investigator’s choice chemotherapy in approximately 460 previously treated metastatic PDAC patients. Median OS was 13.2 months for daraxonrasib versus 6.7 months for chemotherapy. That is nearly double the survival achieved by gemcitabine/nab-paclitaxel or FOLFOX in the second-line setting. The drug targets RAS(ON) mutations, which drive tumor growth in approximately 90% of pancreatic cancer cases, making this a broadly applicable result. Safety was manageable with no new signals. Revolution plans to submit an NDA using an expedited national priority review pathway enabling a one-to-two month review timeline. A first-line PDAC Phase 3 (RASolute 303) is already enrolling. Shares surged on the news.
🔹 Darovasertib + crizotinib (IDEAYA Biosciences / Servier) - Phase 2/3 [OptimUM-02], 1L HLA-A*02:01-negative metastatic uveal melanoma. The regimen met its primary endpoint in 313 patients with median progression-free survival 6.9 months versus 3.1 months. Objective response rate was 37.1% versus 5.8%, including five complete responses in the combination arm. This remains one of the cleanest efficacy signals this week in a hard to treat setting, with overall survival maturity still the key open variable.
🔹 Orforglipron / Foundayo (Eli Lilly) - Phase 3 [ACHIEVE-4], type 2 diabetes with obesity and elevated cardiovascular risk. Lilly dropped the largest and longest Foundayo (orforglipron) trial to date, ACHIEVE-4, covering 2,749 patients with type 2 diabetes and elevated cardiovascular risk across 15 countries. Against insulin glargine, Foundayo met cardiovascular non-inferiority, cut weight by 8.1 kg versus a 1.4 kg gain on the comparator, and reduced A1C by 1.6% versus 1.0%. The headline number that will get attention: all-cause mortality was 57% lower with Foundayo, though that result wasn’t controlled for multiple comparisons so it needs to be interpreted carefully. Lilly plans to file for a type 2 diabetes indication by end of Q2 2026.
WATCHLIST 👀
Merck DOR/ISL (doravirine/islatravir) - PDUFA April 28; if approved, first once-daily two-drug HIV regimen without an integrase inhibitor; watch for any impact on Gilead’s Biktarvy franchise
Viridian Therapeutics / elegrobart - REVEAL-2 (chronic thyroid eye disease) topline data expected Q2 2026; REVEAL-1 (active TED) was positive; BLA filing targeted Q1 2027
IDEAYA / darovasertib+crizotinib - NDA filing H2 2026; first potential approval in first-line uveal melanoma
Revolution Medicines / daraxonrasib - NDA submission timing TBD; ASCO 2026 data presentation upcoming; RASolute 303 (1L PDAC) now enrolling
Eli Lilly / Foundayo (T2D) - NDA submission by end of Q2 2026; FDA will evaluate against ACHIEVE-4 data and post-marketing study framework from obesity approval
Section 232 tariffs - July 31, 2026 effective date for Annex III companies; ADC/cell gene/orphan/plasma-derived biologics remain exempt; watch for pre-July deal acceleration in tariff-exposed modalities
Have a great rest of your week and thanks for reading Biotech Blueprint!
DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.
DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.
LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.
Cover image credit: Pancreatic cancer, illustration Nemes Laszl | Science Photo Library | Getty Images